0000899243-21-049720.txt : 20211223 0000899243-21-049720.hdr.sgml : 20211223 20211223204717 ACCESSION NUMBER: 0000899243-21-049720 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20211217 FILED AS OF DATE: 20211223 DATE AS OF CHANGE: 20211223 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Casdin Eli CENTRAL INDEX KEY: 0001534264 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-40312 FILM NUMBER: 211518696 MAIL ADDRESS: STREET 1: 1350 AVENUE OF THE AMERICAS STREET 2: SUITE 1140 CITY: NEW YORK STATE: NY ZIP: 10019 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: EQRx, Inc. CENTRAL INDEX KEY: 0001843762 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 861691173 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 50 HAMPSHIRE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 6173152266 MAIL ADDRESS: STREET 1: 50 HAMPSHIRE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: CM Life Sciences III Inc. DATE OF NAME CHANGE: 20210201 4/A 1 doc4a.xml FORM 4/A SUBMISSION X0306 4/A 2021-12-17 2021-12-21 0 0001843762 EQRx, Inc. EQRX 0001534264 Casdin Eli EQRX, INC. 50 HAMPSHIRE STREET CAMBRIDGE MA 02139 1 0 1 0 Class A Common Stock 2021-12-17 4 M 0 8659372 A 8659372 I By CMLS Holdings III LLC Class A Common Stock 2021-12-17 4 J 0 8659372 D 0 I By CMLS Holdings III LLC Common Stock 2021-12-17 4 J 0 8659372 A 8659372 I By CMLS Holdings III LLC Common Stock 2021-12-17 4 A 0 25214934 A 25214934 I By Casdin Partners Master Fund L.P. Common Stock 2021-12-17 4 A 0 5000000 10.00 A 30214934 I By Casdin Partners Master Fund L.P. Common Stock 2021-12-17 4 A 0 3824572 A 3824572 I By Casdin Venture Opportunities Fund, L.P. Common Stock 2021-12-17 4 A 0 5488164 A 5488164 I By Casdin Private Growth Equity Fund, L.P. Class B Common Stock 2021-12-17 4 J 0 4840628 D Class A Common Stock 4840628 8659372 I By CMLS Holdings III LLC Class B Common Stock 2021-12-17 4 M 0 8659372 D Class A Common Stock 8659372 0 I By CMLS Holdings III LLC Earn-out Shares 2021-12-17 4 A 0 3454116 A 2024-12-17 Common Stock 3454116 3454116 I By Casdin Partners Master Fund L.P. Earn-out Shares 2021-12-17 4 A 0 523916 A 2024-12-17 Common Stock 523916 523916 I By Casdin Venture Opportunities Fund, L.P. Earn-out Shares 2021-12-17 4 A 0 751807 A 2024-12-17 Common Stock 751807 751807 I By Casdin Private Growth Equity Fund, L.P. Warrants to purchase Class A Common Stock (right to buy) 11.50 2021-12-17 4 A 0 8110001 A 2022-04-09 2026-12-17 Common Stock 8110001 8110001 I By CMLS Holdings III LLC Immediately prior to the consummation of the transactions (the "Closing" of the "Business Combination") contemplated by the Agreement and Plan of Merger dated August 5, 2021 (the "Merger Agreement") by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc., "Legacy EQRx"), each share of the Issuer's Class B Common Stock automatically converted into shares of Class A Common Stock on a one-for-one basis (the "Conversion"). Immediately following the Conversion but prior to Closing, the Class A Common Stock was reclassified as Common Stock. The shares are held directly by CMLS Holdings III LLC. The Reporting Person serves on the Board of Managers of CMLS Holdings III and shares voting and investment discretion with respect to the common stock held of record by CMLS Holdings III LLC. C-LSH III is a member of CMLS Holdings III LLC, and the Reporting Person is managing member of C-LSH III. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Upon consummation of the Business Combination, each share of Legacy EQRx capital stock was exchanged, pursuant to the Merger Agreement, for shares of the Issuer's Common Stock. The shares are held directly by Casdin Partners Master Fund, L.P. ("CPMF"). Casdin Capital, LLC is the investment advisor to CPMF, Casdin Venture Opportunities Fund, L.P. ("CVOF") and Casdin Private Growth Equity Fund, L.P. ("CPGEF"). Casdin Partners GP, LLC is the general partner of CPMF. Casdin Venture Opportunities Fund GP, LLC is the general partner of CVOF. Casdin Private Growth Equity Fund GP, LLC is the general partner of CPGEF. The Reporting Person is the managing member of Casdin Capital, LLC, Casdin Partners GP, LLC, Casdin Venture Opportunities Fund GP, LLC and Casdin Private Growth Equity Fund GP, LLC and may be deemed to have voting and investment power with respect to the shares. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein, if any. Represents shares of Common Stock obtained in a private placement of public securities ("PIPE") on December 17, 2021. The shares are held directly by CVOF. The shares are held directly by CPGEF. Represents shares of Class B Common Stock forfeited to the Issuer for no consideration in connection with the Business Combination. In connection with the Business Combination, the Reporting Person received the right to acquire an aggregate of 4,729,839 shares of the Issuer's Common Stock (the "Earn-out Shares"), (i) 3,310,887 of which will be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 1,418,952 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Merger Agreement. Following the completion of the Business Combination, warrants to purchase Class A Common Stock become exercisable on April 9, 2022. This Form 4 amends and restates the Form 4 filed by the Reporting Persons on December 21, 2021 to clarify the form of ownership reported in Table I and report Earn-out Shares in Table II. Exhibit 24 - Power of Attorney /s/ William Collins, Attorney-in-Fact 2021-12-23 EX-24 2 attachment1.htm EX-24 DOCUMENT

                           LIMITED POWER OF ATTORNEY

        The undersigned hereby constitutes and appoints each of Dina Ciarimboli,
Melanie Nallicheri and Jami Rubin of EQRx, Inc., a Delaware corporation (the
"Company"), and each of William Collins and Marianne Sarrazin of Goodwin Procter
LLP, signing singly, and with full power of substitution, the undersigned's true
and lawful attorney-in-fact to:

        (1) execute for and on behalf of the undersigned, in the undersigned's
capacity as an officer and/or director of the Company, from time to time the
following U.S. Securities and Exchange Commission ("SEC") forms: (i) Form ID,
including any attached documents (such as Update Passphrase Authentication), to
effect the assignment of codes to the undersigned to be used in the transmission
of information to the SEC using the EDGAR System; (ii) Form 3, Initial Statement
of Beneficial Ownership of Securities, including any attached documents; (iii)
Form 4, Statement of Changes in Beneficial Ownership of Securities, including
any attached documents; (iv) Form 5, Annual Statement of Beneficial Ownership of
Securities in accordance with Section 16(a) of the Securities Exchange Act of
1934, as amended, and the rules thereunder, including any attached documents;
(v) Schedules 13D and 13G; and (vi) amendments of each thereof, in accordance
with the Securities Exchange Act of 1934, as amended, and the rules thereunder,
including any attached documents;

        (2) do and perform any and all acts for and on behalf of the undersigned
that may be necessary or desirable to complete and execute any such Form 3, 4 or
5, Schedule 13D or 13G, or any amendment(s) thereto and timely file such form(s)
with the SEC and any securities exchange, national association or similar
authority; and

        (3) take any other action of any type whatsoever in connection with the
foregoing that, in the opinion of such attorney-in-fact, may be of benefit to,
in the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may approve in such
attorney-in-fact's discretion.

        The undersigned hereby grants to each such attorney-in-fact, acting
singly, full power and authority to do and perform any and every act and thing
whatsoever requisite, necessary or proper to be done in the exercise of any of
the rights and powers herein granted, as fully to all intents and purposes as
the undersigned might or could do if personally present, with full power of
substitution or revocation, hereby ratifying and confirming all that such
attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall
lawfully do or cause to be done by virtue of this power of attorney and the
rights and powers herein granted.  The undersigned acknowledges that the
foregoing attorneys-in-fact, in serving in such capacity at the request of the
undersigned, are not assuming, nor is the Company assuming, any of the
undersigned's responsibilities to comply with Section 16 or Regulation 13D-G of
the Securities Exchange Act of 1934, as amended.  The undersigned hereby agrees
to indemnify the attorneys-in-fact and the Company from and against any demand,
damage, loss, cost or expense arising from any false or misleading information
provided by the undersigned to the attorneys-in-fact.

        This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file such forms with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact.  This Power of Attorney supersedes any prior power
of attorney in connection with the undersigned's capacity as an officer and/or
director of the Company.  This Power of Attorney shall expire as to any
individual attorney-in-fact if such attorney-in-fact ceases to be an employee
of the Company or Goodwin Procter LLP, as the case may be.

        IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to
be executed as of December 17, 2021.

                                        /s/ Eli Casdin
                                        ------------------------
                                        Signature

                                        Eli Casdin
                                        ------------------------
                                        Print Name